免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展*

doi:10.3969/j.issn.1672-5069.2023.03.039

Abstract

Abstract: Immune checkpoint inhibitor is a kind of cancer immunotherapy agents, which has anti-tumor activities by improving immune microenvironment around the tumors. The hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the treatment efficacy of advanced disease is poor. The immune checkpoint inhibitors have a certain effects on advanced HCC. In this article, we will review the mechanism, treatment and adverse events of immune checkpoint inhibitors in treating patients with advanced HCC.

Key words: Hepatocellular carcinoma, Immune checkpoint inhibitors, Therapy, Adverse events

Chen Peng, Liu Huan, Xu Liang. Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2023, 26(3): 453-456.

References

[1] Brar G, Greten T.F, Graubard B.I, et al. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis.Hepatol Commun, 2020, 4:1541-1551.
[2] Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer treat Rev, 2019,77:20-28.
[3] Saffo S, Taddei TH. Systemic management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digest Dis Sci, 2019,64 (4):1016-1029.
[4] Collier JL, Weiss SA, Pauken KE, et al. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol, 2021, 22(7):809-819.
[5] Huyen PTM, Dung DTN, Weiß PJ, et al. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression. Int J Infect Dis, 2022,115:229-236.
[6] Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol, 2020,1248:7-32.
[7] Gomez S, Tabernacki T, Kobyra J, et al. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol, 2020, 65:99-113.
[8] Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res, 2018, 48:597-607.
[9] Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther, 2018, 18(12): 1169-1175.
[10] Yau T,Park J.W,Finn R.S,et al. LBA38_PR-CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol, 2019, 30: v874-v875.
[11] Lim Chiew Woon, Lee Joycelyn Jie Xin, Choo Su Pin, et al. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther, 2020,20(7):687-693.
[12] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-randomised,open-label phase 2 trial. Lancet Oncol, 2018,19 (7):940-952.
[13] Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol, 2020,38(3):193-202.
[14] Feun LG, Li YY, Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer, 2019, 125(20):3603-3614.
[15] Yu R, Wang W, Li T, et al. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. Future Oncol, 2021, 17(31):4081-4089.
[16] Jinzhang Chen, Xiaoyun Hu, Qi Li, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med, 2020,8(18):1187.
[17] Maestri M, Pallozzi M, Santopaolo F, et al. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opin Investig Drugs, 2022,31(4):347-360.
[18] Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol, 2013,59:81-88.
[19] Silva IP, Long GV. Systemic therapy in advanced melanoma: Integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol, 2017, 29:484-492.
[20] Zhou G, Sprengers D, Boor PPC, et al. Anti-bodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells inhepatocellular carcinomas. Gastroenterology, 2017,153:1107-1119.e10.
[21] Thomas Yau, Yoon-Koo Kang, Tae-You Kim, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol, 2020,6(11):e204564.
[22] Kevin Wright. FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC. Oncology (Williston Park), 2020,34(4):693606.
[23] Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer, 2021,9(2):e001945.
[24] Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol, 2017,35(15_suppl):4073.
[25] Kelley RK, Sangro B, Harris WP, et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J Clin Oncol, 2020, 38(suppl):4508.
[26] Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020,382(20):1894-1905.
[27] Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer, 2020, 137:272-284.
[28] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol, 2020, 38(26): 2970.
[29] Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res, 2021, 27(4):1003-1011.
[30] Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J. Gastroenterol, 2019, 25:789-807.
[31] El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer, 2019, 125(19):3312-3319.
[32] Ahmed Montasser, Aurélie Beaufrère, François Cauchy, et al. Transarterial chemoembolization enhances programmed death 1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79(1):36-46.
[33] Zheng L, Fang S, Wu F, et al. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci, 2021,7:609322.
[34] Xu ZN, Huang JJ, Zhou J, et al. Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy. Zhonghua Nei Ke Za Zhi, 2021, 60(7):630-636.
[35] Chao J, Zhu Q, Chen D, et al. Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Front Oncol, 2021,11:667555.

Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[2]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.
[3]	Wang Yunyun, Wu Wanfeng, Li Li. Antiviral efficacy and impact on blood glucose control of direct acting antivirals in treatment of patients with genotype 1b chronic hepatitis C and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(3): 344-347.
[4]	Xu Haimiao, Zheng Ruiqi, Ding Huiguo. Short-term efficacy of pitavastatin and polyene phosphatidyl choline combination in the treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 352-355.
[5]	Guo Yinyan, Yue Zhi, Gai Xiaodong, et al.. Clinical and liver pathological features of patients with autoimmune hepatitis- primary biliary cholangitis overlap syndrome [J]. Journal of Practical Hepatology, 2023, 26(3): 372-375.
[6]	Wang Junhong, Dai Ling, Chen Guobin, et al.. Cost-effectiveness analysis of reduced glutathione,diammonium glycyrrhizinate and glycyrrhizin in the treatment of patients with anti-tuberculosis medicine-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 380-383.
[7]	Wei Dongping, Han Lili, Ling Jiahui, et al.. Efficacy of glycyrrhizic acid diamine and compound glycyrrhizin in the treatment of patients with cyclophosphamide-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 388-391.
[8]	Liu Kun, Xu Jing, Ma Zhufang. Transient improvement of patients with liver cirrhosis-induced refractory ascites by oral tolvaptan administration at base of concentrated ascites reinfusion [J]. Journal of Practical Hepatology, 2023, 26(3): 396-399.
[9]	Tang Liang, Chen Xi, Wang Wengao. Short-term clinical efficacy of TACE and 3D-CRT in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(3): 416-419.
[10]	Zhang Wei, Chen Guolin, Wang Hang, et al.. Clinical feature of patients with pyogenic liver abscess with different underlying diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 424-427.
[11]	Zhang Qiong, Chen Shiying, Xia Wei. Comparison of anhydrous ethanol and lauromacrogol sclerotherapy under ultrasound guidance in the treatment of patients with simple hepatic cysts [J]. Journal of Practical Hepatology, 2023, 26(3): 428-431.
[12]	Wu Zhengdong, Xu Gang, Mu Haifeng, et al.. Early LC after ERCP and EST is beneficial in the treatment of patients with simultaneous gallbladder and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(3): 432-435.
[13]	Zhu Ligang, Wang Tao, Zhou Weiwei, et al.. Comparison of laparoscopic hepatectomy and percutaneous transhepatic choledochoscopic lithotomy in the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(3): 436-439.
[14]	Zhong Huan, Ye Wei. Very short-term observation of avatrombopag for the treatment of patients with liver cirrhosis and primary liver cancer and thrombocytopenia [J]. Journal of Practical Hepatology, 2023, 26(3): 440-442.
[15]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.